NYSE · Pharmaceuticals
ABBVAbbVie Inc.
$260.21
▼ $1.51 (-0.58%)
15-min delayed · via Finnhub
Loading chart…
📊 Wall Street Consensus
39 analysts rating ABBV
Buy
consensus
Strong Buy
10 (26%)
Buy
22 (56%)
Hold
7 (18%)
Sell
0 (0%)
Strong Sell
0 (0%)
As of Sep 2026 · Aggregated US analyst ratings via Finnhub
Data on AbbVie Inc.
Recent ABBV News
Pharmaceuticals
AbbVie Acquisition of Evommune Reshapes Immunology Startup Outlook with Full Development Infrastructure Access
AbbVie's acquisition of Evommune, a clinical-stage immunology startup, materially improves the target company's development outlook by providing access to AbbVie's global clinical infrastructure and commercial capabilities for inflammatory skin condition programs.
Jun 23, 2026
🇺🇸 United StatesApogee Therapeutics (APGE) Stock Surges Sharply on AbbVie Acquisition News
APGE shares spike sharply on AbbVie acquisition announcement and premium pricing.
Jun 23, 2026
🇺🇸 United StatesAbbVie (ABBV) Acquires Apogee Therapeutics, Impact on Regeneron Analyzed
AbbVie acquires Apogee Therapeutics to strengthen immunology and atopic dermatitis pipeline.
Jun 23, 2026
About AbbVie Inc.
Similar Stocks
Data shown is informational only and may be delayed by up to 15 minutes. Not a recommendation to buy, sell, or hold any security. See our disclaimer.